Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
B-Cell lymphoma comprises a diverse group of blood cancers arising from abnormal B lymphocytes, ranging from slow-growing follicular lymphoma to aggressive diffuse large B-cell lymphoma. These malignancies account for about 85% of non-Hodgkin lymphoma cases, underscoring their substantial disease burden. The B-Cell Lymphoma pipeline analysis by Expert Market Research highlights growing development of bispecific antibodies, antibody-drug conjugates, CAR-T therapies, targeted inhibitors, and next-generation immunotherapies aimed at improving durable responses, reducing relapse, and expanding treatment options for heavily pretreated patients worldwide.
-
Major companies involved in the B-Cell Lymphoma pipeline analysis include Jiangsu Topcel-KH Pharmaceutical Co., Ltd., Taiho Oncology, Inc. and others.
-
Leading drugs currently in the pipeline include BTM-3566 and others.
-
The pipeline is being propelled by next-generation bispecific antibodies, CAR-T cell refinements, and antibody-drug conjugates targeting resistant disease biology. Biomarker-guided patient selection, off-the-shelf cellular therapies, and combination immunotherapy strategies are expanding treatment options, improving durability of response, and accelerating differentiated clinical development across relapsed and refractory B-cell lymphoma indications.
Report Coverage
The B-Cell Lymphoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into B-Cell Lymphoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for B-Cell Lymphoma. The B-Cell Lymphoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The B-Cell Lymphoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with B-Cell Lymphoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to B-Cell Lymphoma.
Read more about this report - Request a Free Sample
B-Cell Lymphoma Pipeline Outlook
The B-cell lymphoma pipeline continues to advance with expanding regulatory support for innovative cellular immunotherapies targeting relapsed and refractory disease. For instance, in December 2025, the U.S. FDA approved Breyanzi (lisocabtagene maraleucel) for adults with relapsed or refractory marginal zone lymphoma after at least two prior systemic therapies, broadening its B-cell lymphoma indications. This approval reinforces confidence in CAR-T therapies, encourages continued investment in next-generation immunotherapies, and is expected to accelerate pipeline development and improve treatment options for patients.
B-Cell Lymphoma Epidemiology
B-cell lymphoma represents 85-90% of non-Hodgkin lymphoma cases worldwide. GLOBOCAN 2024 estimated 562,793 new non-Hodgkin lymphoma cases and 234,903 deaths globally, with Asia accounting for 44.5% of diagnoses. B-cell lymphoma incidence reaches about 20 cases per 100,000 people annually in high-income countries. Disease burden rises sharply with age and remains higher among men. Diffuse large B-cell lymphoma is the most common aggressive subtype, and follicular lymphoma remains a leading indolent form in many national registries across adult and older populations.
B-Cell Lymphoma – Pipeline Therapeutic Assessment
This section of the report covers the analysis of B-Cell Lymphoma drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The B-Cell Lymphoma pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
B-Cell Lymphoma Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total B-Cell Lymphoma clinical trials. Early Phase I accounted for 3.59%, Phase I for 35.03%, Phase II for 51.30%, Phase III for 8.78%, and Phase IV for 1.30%, highlighting a strong concentration of candidates in mid-stage clinical development and ongoing therapeutic innovation.
B-Cell Lymphoma Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the B-Cell Lymphoma pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The B-Cell Lymphoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for B-Cell Lymphoma. In June 2024, The U.S. FDA granted accelerated approval to Epkinly (epcoritamab-bysp) for adults with relapsed or refractory follicular lymphoma after two or more prior lines of systemic therapy, expanding its use across B-cell lymphoma indications.
B-Cell Lymphoma Clinical Trials – Key Players
The EMR report for the B-Cell Lymphoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed B-Cell Lymphoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in B-Cell Lymphoma clinical trials:
- Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
- Bantam Pharmaceuticals
- Medolution Ltd.
- Celgene
- Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.
- Iksuda Therapeutics Ltd.
- Guangzhou Lupeng Pharmaceutical Company Ltd.
- ADC Therapeutics S.A.
- Taiho Oncology, Inc.
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Nanjing IASO Biotechnology Co., Ltd.
- TCRx Therapeutics Co., Ltd.
B-Cell Lymphoma – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for B-Cell Lymphoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of B-Cell Lymphoma drug candidates.
Biological: CTL019
CTL019, marketed as Kymriah (tisagenlecleucel), is a CAR-T cell therapy developed by Novartis for relapsed or refractory B-cell lymphoma. It genetically modifies a patient's T cells to express a CD19-targeting chimeric antigen receptor, enabling selective destruction of malignant B cells. Although approved for several B-cell malignancies, ongoing post-marketing and label-expansion studies are expected to continue through 2027. Novartis is a global pharmaceutical leader with extensive expertise in oncology, cell therapies, and advanced biologic innovation.
Biological: IgPro20
IgPro20, marketed as Hizentra, is a subcutaneous human immunoglobulin (IgG) biological developed by CSL Behring. In patients with B-cell lymphoma, it is being investigated to reduce secondary immunodeficiency and recurrent infections associated with lymphoma treatment and B-cell depletion therapies. Ongoing clinical studies are expected to reach completion in 2026. CSL Behring is a global biotechnology company specializing in plasma-derived therapies, immunology, hematology, and innovative treatments for rare and immune-related diseases.
Drug: BGB-16673 | Drug: Pirtobrutinib
BGB-16673 is an investigational small-molecule BTK degrader developed by BeiGene, while Pirtobrutinib is a non-covalent BTK inhibitor developed by Eli Lilly and Company. Both target Bruton's tyrosine kinase through different mechanisms to overcome resistance to earlier BTK inhibitors in relapsed or refractory B-cell lymphoma. Clinical studies are expected to conclude between 2027 and 2028. BeiGene and Eli Lilly continue expanding precision oncology portfolios through globally coordinated hematologic malignancy development programs.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the B-Cell Lymphoma Pipeline Insight Report
- Which companies/institutions are leading the B-Cell Lymphoma drug development?
- Which company is leading the B-Cell Lymphoma pipeline development activities?
- What is the current B-Cell Lymphoma commercial assessment?
- What are the opportunities and challenges present in the B-Cell Lymphoma pipeline landscape?
- What is the efficacy and safety profile of B-Cell Lymphoma pipeline drugs?
- Which company is conducting major trials for B-Cell Lymphoma drugs?
- Which companies/institutions are involved in B-Cell Lymphoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in B-Cell Lymphoma?
Reasons To Buy This Report
The B-Cell Lymphoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for B-Cell Lymphoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into B-Cell Lymphoma collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
